Lymphoma Hub continues to provide the latest updates and innovations in lymphoma treatment and research

Press release: Available for immediate release

The Lymphoma Hub, run by Scientific Education Support in partnership with the European Lymphoma Institute, is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in lymphoma. During Q4 of 2021 the Lymphoma Hub has continued to provide news on clinical trials and drug updates, key literature, expert video interviews, and international congress coverage.

Later in October, the Lymphoma Hub provided highlights from the Lymphoma Leukemia & Myeloma 2021 Virtual Congress. We updated our audience on emerging data, innovative treatment methods, and the future of lymphoma, myeloma, and leukemia disorders.

Another interesting event covered by the Lymphoma Hub in the same period was the 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021). We brought updates on talks from eminent speakers and specialists with expertise in the spectrum of hematologic diseases. Emphasis was given to the cutting-edge advances and practical clinical applications for the optimization of transplantation and cellular therapies.

In Q4, Lymphoma Hub held a virtual meeting with the members of our prestigious steering committee and scientific advisory board, focusing on determining more robust and valuable scientific content that will be added to the Lymphoma Hub in the coming months.

The Lymphoma Hub also covered the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, utilizing a hybrid model of both in-person and virtual participation in order to deliver the best possible content.

Reviewing the Lymphoma Hub’s impact this quarter, Mia Hill, IME Director at Scientific Education Support, said:

“We are delighted with the progress made by the Lymphoma Hub during this quarter. As the year draws to a close, our website users and page views continue to grow, with just under 250,000 page views for the hub so far this year. This sets the hub up for a very successful 2022 with solid foundations for us to continue to expand our audience. Reporting at such a prestigious congress enabled us to share the opinions of experts in the field, covering cutting-edge research, new treatments, and diagnostic strategies.”

Activity such as this would not be possible without our supporters. We would like to take this opportunity to welcome our new supporter Pharmacyclics and also show our gratitude for our existing supporters—Bristol Myers Squibb, Incyte, Roche, ADC Therapeutics, Genentech, Novartis, Epizyme, Karyopharm Therapeutics, TG Therapeutics.

ENDS

For more information on the Lymphoma Hub, please visit lymphomahub.com.

For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com or Barry.Connolly@scientificeducationsupport.com.

NOTES TO EDITOR

About lymphoma

Lymphoma is described as the development of neoplastic cellular growth—cancer—in the lymphatic system. Lymphomas are divided into two major categories: Hodgkin and non-Hodgkin lymphomas, where the latter is more common.

About the Lymphoma Hub

The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge of lymphoma and CLL through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

The Lymphoma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the Lymphoma Hub supports HCPs worldwide.

Founded in partnership with the European Lymphoma Institute (ELI) in 2014, the Lymphoma Hub is guided by an international steering committee of experts in the field of lymphoma and CLL. The steering committee meet regularly to discuss the performance of the Lymphoma Hub and to devise action plans on how best to support the lymphoma community and address any unmet educational needs.

Lymphoma Hub supporters

Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.

• Bristol Myers Squibb
• Incyte
• Roche
• Genentech
• Novartis
• ADC Therapeutics
• Epizyme
• Karyopharm Therapeutics
• TG Therapeutics
• Pharmacyclics

If you are interested in becoming a Lymphoma Hub supporter, please contact secretariat@scientificeducationsupport.com.

About Scientific Education Support (SES)

SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the ALL Hub, AML Hub, GvHD Hub, MDS Hub, MPN Hub, and Multiple Myeloma Hub.

About The European Lymphoma Institute (ELI)

Lymphoma, the sixth cancer worldwide in terms of incidence, is a complex disease. ELI, The European Lymphoma Institute, regroups top European specialists in the field of lymphoma within a net dedicated to research, training and education. To date, thirteen European academic research groups have come together in an effort to define strategies to analyze and characterize this cancer, common diagnostic procedures and therapeutic standards as well as to facilitate clinical and fundamental research at the European level.